{"id":"full-course-of-pd-1-monoclonal-antibody","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Fatigue"},{"rate":"15–25","effect":"Diarrhea"},{"rate":"10–20","effect":"Nausea"},{"rate":"3–5","effect":"Immune-related pneumonitis"},{"rate":"2–5","effect":"Immune-related hepatitis"},{"rate":"2–4","effect":"Immune-related colitis"},{"rate":"10–15","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PD-1 is an immune checkpoint receptor that, when engaged by tumor-expressed ligands (PD-L1/PD-L2), suppresses T-cell activation and allows tumors to evade immunity. PD-1 monoclonal antibodies prevent this inhibitory signal, thereby reactivating exhausted T cells and enhancing their ability to recognize and kill cancer cells. This mechanism has proven effective across multiple solid and hematologic malignancies.","oneSentence":"A monoclonal antibody that binds to PD-1 on immune cells, blocking the interaction with PD-L1/PD-L2 on tumor cells and restoring anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:35.131Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic melanoma"},{"name":"Non-small cell lung cancer"},{"name":"Renal cell carcinoma"},{"name":"Hodgkin lymphoma"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07328854","phase":"PHASE3","title":"40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-20","conditions":"Nasopharyngeal Carcinoma","enrollment":346},{"nctId":"NCT05594381","phase":"PHASE2","title":"A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-10","conditions":"Gastric Cancer","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Full course of PD-1 monoclonal antibody","genericName":"Full course of PD-1 monoclonal antibody","companyName":"Ming-Yuan Chen","companyId":"ming-yuan-chen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A monoclonal antibody that binds to PD-1 on immune cells, blocking the interaction with PD-L1/PD-L2 on tumor cells and restoring anti-tumor immune responses. Used for Advanced or metastatic melanoma, Non-small cell lung cancer, Renal cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}